| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 |
| Net income | -15.6 | -3.2 |
| EPS (diluted, $ a share) | $0.11 | $0.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ENTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Entera Bio Ltd.: key numbers
- Share price
- $3.02Close, Nov 16
- Market cap
- $526M
- Shares outstanding
- 174.14MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Entera Bio Ltd.
All →Entera Bio Financial Results
Entera Bio reported financial results for the third quarter of 2026, highlighting preparations for its Phase 3 study of EB613 in osteoporosis with site activation expected in late 2026. The company significantly expanded its leadership team with several senior clinical appointments and new board members to support late-stage execution. Net loss for the quarter was $3.1 million, with a cash position of $11.4 million as of September 30, 2026.
- Term
- Q3 2026
“The third quarter of 2026 transitioned our expanding team into late-stage clinical execution mode. The opportunity to evaluate the safety and efficacy of EB613 as the first oral anabolic treatment for osteoporosis has generated excitement among clinical investigators and patients.”
Miranda Toledano, Chief Executive Officer of Entera
Entera Bio Leadership Change
Entera Bio Ltd. appointed Dr. Juan Camilo Arjona Ferreira, currently the CMO of Organon & Co., as a Class II director effective December 1, 2026. Simultaneously, Haya Taitel notified the board of her resignation as a director, also effective December 1, 2026. Dr. Arjona Ferreira will participate in the company's standard non-employee director compensation program.
Entera Bio Leadership Change
Entera Bio appointed Laura Hamill, a former executive at Gilead and Amgen, to its Board of Directors effective December 1, 2026. She replaces Yonatan Malca, who is stepping down from the Board after 16 years of service. Ms. Hamill will serve on the audit and corporate governance committees and participate in the company's standard non-employee director compensation plan.